학술논문

A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Thl- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.
Document Type
Article
Source
Clinical & Experimental Immunology. Aug1995, Vol. 101 Issue 2, p265-271. 7p.
Subject
*CANCER treatment
*IMMUNOGLOBULINS
*LYMPHOCYTES
*PREVENTIVE medicine
*MEMBRANE proteins
*PAPILLOMAVIRUSES
Language
ISSN
0009-9104
Abstract
TraT protein, known as ISCAR (==Immunostimulatory Carrier), is one of a family of integral membrane proteins (Imps) of Escherichia coli representing powerful carrier molecules which when injected into experimental animals generate substantial antibody and T proliferative responses to molecules conjugated to it. We extend these findings to show that ISCAR functions to stimulate Th1- and Th2-type responses, including specific cytotoxic T cells and tumour protection. We report here that by conjugating to ISCAR a I9nier peptide containing linear B epitopes, a T helper (Th) epitope, and a H-2b-restricted T cytotoxic (CTL) epitope of E7 protein of human papillomavirus type 16 (HPVI6), and immunizing C57B1/6 (H-2b) mice, we elicited (i) specific IgG2a and IgG 1 antibodies; (ii) IL-2 and IL-4 production by specifically recalled lymph node cells in vitro, (iii) cytotoxic T lymphocytes which specifically killed both E7 peptide-pulsed, and whole E7 gene-trans feet ed tumour target cells: and (iv) in vivo protection against an E7 gene-transfected tumour cell inoculum. These findings have implications for the design of vaccines to stimulate immune responses to endogenously processed target antigens (e.g. tumour-associated antigens) without the unwanted side effects of oil-based adjuvants. In addition they support the case for a E7-targeted therapeutic vaccine for HPV-associated human cervical cancer. [ABSTRACT FROM AUTHOR]